

Q2FY25 Result Update

Krishna Institute of Medical Sciences

Capacity expansion to drive growth

- Krishna Institute of Medical Sciences (KIMS) delivered a strong Q2FY25 performance, surpassing our estimates on all fronts. It saw a 19% YoY growth in revenues driven by a 9%/12% YoY growth in IP/OP volumes, a 23% YoY growth in ARPOB, and a 10% YoY growth in ARPP in Q2FY25. However, occupancy saw a dip to 49.7% (but flattish QoQ) due to operationalisation of 625 new beds.
- KIMS has operationalised its Nashik unit (325-bed) and its recent acquisition, Queen's NRI at Vizag (300-bed) during the quarter taking its total bed capacity to 4,610 beds.
- EBITDA margin saw an expansion of 89bp YoY to 28.1% in Q2FY25 despite adding new units. The management expects to sustain EBITDA margins at 27-28% for FY25.
- The company also entered in Operations and Management (O&M) agreements with two hospitals; i) Kannur (200-beds) and ii) Guntur (200-beds) which are expected to start operations in Q3FY25. Including hospitals brought under O&M (400-beds), the total bed capacity of KIMS will reach ~5,000 beds in FY25 as compared to 3,975 in FY24.
- We raise our EBITDA estimates by 4%/8% for FY25/FY26 to factor in better EBITDA margins in mature hospitals and addition of beds under O&M. We also introduce estimates for FY27 and rollover the valuation to average EBITDA for FY26E/FY27E to deduce a price target of INR630, based on 22x EV/EBITDA (earlier INR512, based on 22x FY26 EV/EBITDA)

Strong growth seen in financial parameters:

KIMS' revenue grew 19% YoY and 13% QoQ to INR777cr on the back of a strong growth seen across all operating parameters. EBITDA was seen at INR218cr, up 23% YoY and 22% QoQ with an EBITDA margin expansion of 89bp YoY and 200bp QoQ to 28.1% on the back of better operating leverage. PAT grew 19% YoY and 27% QoQ to INR121cr. KIMS is on track to achieve our FY25 estimates with a revenue/EBITDA/PAT contribution of 49%/49%/51% during H1FY25. We have built in a revenue/EBITDA/PAT CAGR of 27%/27%/32% over FY24-27.

Healthy improvement across operating parameters:

The operating parameters witnessed a healthy improvement across all parameters. In-patient (IP) volumes grew 9.1% YoY to 55,741 patients, out-patient (OP) volumes grew 12.2% YoY to 4,73,989 patients, ARPOB grew 22.9% YoY to INR38,263, ARPP grew 9.7% YoY to INR1,40,316 and ALOS fell 11% YoY to 3.67 days. On a QoQ basis, the IP volumes/OP volumes/ARPP grew 12.2%/12.5%/0.7% respectively while ARPOB fell marginally by 0.5%. ALOS was up 1% QoQ. The occupancy rate saw dip during the quarter to 49.7%, vs. 49.8% in Q1FY25 and 57.4% in Q2FY24 due to commencing operations at the new units.

Margin likely to sustain:

KIMS saw a 89bp YoY and 200bp QoQ EBITDA margin expansion to 28.1% despite commencing operations at its new units. The margins are expected to sustain for the second half of FY25 and ramping up of the newly commenced units would help in margin expansion going forward.

Capacity expansions to drive growth:

KIMS has multiple capex plans in progress, to add ~1,800 beds in two years through various greenfield and brownfield plans. With some commencing operating later in FY25. Revenue for KIMS is likely to be boosted on the back of these expansions. The brownfield expansions include: i) Kondapur (~ 500 beds in a phased manner up to Q1FY27), ii) Anantapur (250 beds by Q4FY26), iii) Srikakulam (120 beds by Q4FY25) and iv) Ongole (50 beds by Q4FY25). Its greenfield plans include: i) Bangalore – Project 1 (415 beds by Q4FY25), ii) Bangalore – Project 2 (250 bed by Q4FY25) and iii) Thane (300 beds by Q4FY25). The company has also entered into O&M agreements for two hospitals, one in Kannur (200-beds) and one in Guntur (200-beds), which are likely to commence in Q3FY25. The capex requirements would be managed via internal accruals with minimal dependence of debt.

Valuation and View:

KIMS Hospitals has multiple expansion plans in place, few of them (Thane, Bangalore, Srikakulam and Ongole units) would be commencing operations in H2FY25. A 22% YoY growth in ARPOB in H1FY25 gives confidence of better-than-expected ARPOB for FY25. KIMS would be adding ~1,025 beds (including 400 beds under O&M) during FY25 and ~1,135 beds in FY26, which implies 26%/23% expansion in total bed capacity during FY25/FY26. We expect a revenue/EBITDA/PAT CAGR of 27%/27%/32% during FY24-27E. We retain our 'BUY' rating on the stock with TP of INR630.

Key financials

Particulars	Q2FY25	Q2FY24	% YoY	Q1FY25	% QoQ	FY25E	FY26E	FY27E
Revenue (INRcr)	777	652	19	688	13	3,011	4,203	5,137
EBITDA	218	177	23	179	22	804	1,079	1,317
EBITDA margin (%)	28	27	89bp	26	200bp	27	26	26
Net Profit	121	101	19	95	27	394	574	719
Diluted EPS	3	3	19	2	27	10	14	18
Diluted P/E (x)						57	39	31
EV/EBITDA (x)						29	22	18
ROCE(%)						18	22	23

CMP: INR563


Rating: BUY

Target price: INR630

Upside: 11%

Date: November 12, 2024

Bloomberg:	KIMS:IN
52-week range (INR):	350 /604
M-cap (INR cr):	22,687
Promoter holding (%)	38.82



Thakur Ranvir Singh
ranvir.singh@nuvama.com

Pawan Bhatia
pawan.bhatia@nuvama.com

Capacity expansion to drive growth

Q2FY25 result highlights

Particulars (INR cr)	Q2FY25	Q2FY24	YoY%	Q1FY25	QoQ%	H1FY25	H1FY24	% YoY	FY25E	FY26E	FY27E
Net Revenues	777	652	19.1	688	13	1,466	1,258	16.5	3,011	4,203	5,137
Cost of goods sold	156	140	11	143	9	298	270	10	632	883	1,079
Gross Profit	622	512	21	546	14	1,168	988	18	2,379	3,320	4,058
Operating expenses	404	335	21	366	10	770	654	18	1,574	2,241	2,742
EBITDA	218	177	23	179	22	398	334	19	804	1,079	1,317
EBITDA margin	28	27	89bp	26	200bp	27	27	56bp	27	26	26
Depreciation and amortization	41	33	26	39	5	80	65	23	180	210	257
EBIT	177	145	22	140	26	318	269	18	625	868	1,060
Interest expenses	20	9	123	18	11	38	18	107	77	79	75
Other income	5	3	73	5	9	10	6	60	20	22	24
PBT	162	139	17	127	28	289	257	12	568	811	1,009
Provision for tax	42	37	11	32	30	73	69	6	148	211	262
Core profit	121	101	19	95	27	216	188	15	420	601	747
Extraordinary Items	-	-	-	-	-	-	-	-	-	-	-
Profit after tax	121	101	19	95	27	216	188	15	420	601	747
Adjusted PAT	121	101	19	95	27	216	188	15	394	574	719
EPS (INR)	3	3	19	2	27	5	5	15	10	14	18
As % of net revenues											
COGS	20	22	-151bp	21	-71bp	20	21	-115bp	21	21	21
Operating expenses	52	51	62bp	53	-129bp	53	52	59bp	52	53	53
EBITDA	28	27	89bp	26	200bp	27	27	56bp	27	26	26
Reported net profit	16	16	0bp	14	170bp	15	15	-21bp	14	14	15
Tax rate (%)	26	27	-133bp	25	49bp	25	27	-155bp	26	26	26

Operational Matrix

Particulars	Q2FY25	Q2FY24	% YoY	Q1FY25	QoQ%	H1FY25	H1FY24	% YoY	FY25E	FY26E	FY27E
Occupied Beds	2,292	2,283	0.4	1,979	16	2,188	2,194	-0.3	2,440	2,869	3,412
Occupancy Rate %	49.7	57.4	-770bp	49.8	-10bp	47.5	55.2	-770bp	59.5	61.7	62.6
ARPOB (INR)	38,263	31,140	23	38,458	-1	38,400	31,400	22.3	33,520	39,613	40,640
ARPP (INR)	1,40,316	1,27,959	10	1,39,398	1	1,39,884	1,29,575	8.0	1,28,570	1,52,633	1,56,886
IP volume	55,741	51,115	9	49,674	12	1,05,000	97,000	9.1	2,34,188	2,75,342	3,27,443
OP volume	4,73,989	4,22,499	12	4,21,367	12	8,95,000	8,05,000	12.2	19,96,177	23,46,962	27,91,058
ALOS (days)	3.7	4.1	-11	3.6	1.4	3.7	4.1	-10.7	3.8	3.5	3.5

Revised Estimates	FY25E			FY26E			FY27E
	Previous	Revised	% changes	Previous	Revised	% changes	New
Sales	2,971	3,011	1	4,001	4,203	5	5,137
EBITDA	771	804	4	995	1,079	8	1,317
EBITDA margin (%)	26	27	77bp	25	26	80bp	26
Adjusted PAT	353	394	12	476	574	21	719
Basic EPS	44	10	-78	59	14	-76	18

*The EPS reflects a split of equity shares from a FV of ₹10 to FV of ₹2 per share.

Capacity expansion to drive growth

Previous outlook

Q1FY25: KIMS Hospitals has a strong trajectory of expansion plans for the next 3 years, which should increase the total bed capacity to ~6,300 in FY27 from 3,975 in FY24 (an expansion of 60%). Key hospitals which were acquired couple of years back like- SunShine Hospitals (Hyderabad), Kingsway Hospital (Nagpur), and Manavata Hospitals (Nashik) are witnessing a stronger traction and has helped fast forward the growth. The recent acquisition of QNRI (Vizag) is set to aid the growth in H2FY25. A strong growth in operating parameters (IP/OP volume, ARPOB, ARPP) along with multiple expansion plans are likely to boost the revenues for KIMS Hospitals going forward.

Q4FY24: KIMS reported weaker-than-expected Q4FY24/FY24 results. It also witnessed a lower occupancy in FY24 at its core hospitals, presumably due to the shifting of KIMS Sun Shine units to new locations, elections in Telangana, and coastal belt impact in Hyderabad. However, there were positive trends seen in the operating parameters which instilled our confidence in the business. It retains a strong balance sheet with a net debt/equity ratio of 0.44x. KIMS plans ~INR1,200cr Capex to add ~1880 beds by Q1FY27, which would be met through internal accruals. We forecast a revenue/EBITDA/PAT CAGR of 23%/22%/19% over FY24-26E. Our target price of INR 2,193 is based on 20x FY26E EV/EBITDA (earlier, INR2,157; 20x FY25E EV/EBITDA).



Capacity expansion to drive growth

Financials

Income statement (Consolidated)

(INR cr)

Year to March	FY22	FY23	FY24	FY25E	FY26E	FY27E
Income from operations	1,651	2,198	2,498	3,011	4,203	5,137
Direct costs	355	481	530	632	883	1,079
Employee costs	262	346	422	482	672	822
Other expenses	780	1,113	1,327	1,574	2,241	2,742
Total operating expenses	1,135	1,594	1,858	2,207	3,124	3,821
EBITDA	516	604	640	804	1,079	1,317
Depreciation and amortisation	73	129	147	180	210	257
EBIT	443	475	494	625	868	1,060
Interest expenses	16	31	47	77	79	75
Other income	20	26	13	20	22	24
Profit before tax	447	470	460	568	811	1,009
Provision for tax	113	119	124	148	211	262
Core profit	334	351	336	420	601	747
Extraordinary items	-	15	-	-	-	-
Profit after tax	334	366	336	420	601	747
Minority Interest	-11	-29	-26	-26	-27	-27
Share from associates	10	-	-0	-	-	-
Adjusted net profit	333	336	310	394	574	719
Equity shares outstanding (cr)	8	8	8	40	40	40
EPS (INR) basic	42	42	39	10	14	18
Diluted shares (Cr)	40	40	40	40	40	40
EPS (INR) fully diluted	8	8	8	10	14	18

Common size metrics- as % of net revenues

Year to March	FY22	FY23	FY24	FY25E	FY26E	FY27E
Operating expenses	68.8	72.5	74.4	73.3	74.3	74.4
Depreciation	4.4	5.9	5.9	6.0	5.0	5.0
Interest expenditure	1.0	1.4	1.9	2.5	1.9	1.5
EBITDA margins	31.2	27.5	25.6	26.7	25.7	25.6
Net profit margins	20.2	15.3	12.4	13.1	13.6	14.0

Growth metrics (%)

Year to March	FY22	FY23	FY24	FY25E	FY26E	FY27E
Revenues	24.1	33.1	13.7	20.5	39.6	22.2
EBITDA	39.1	17.1	6.0	25.6	34.1	22.0
PBT	60.3	5.1	-2.2	23.5	42.8	24.3
Net profit	65.3	1.1	-7.8	27.1	45.6	25.4
EPS	65.3	1.1	-7.8	27.1	45.6	25.4

Q2FY25 Result Update

Krishna Institute of Medical Sciences

Capacity expansion to drive growth

Balance sheet

(INR cr)

as on 31st March	FY22	FY23	FY24	FY25E	FY26E	FY27E
Equity share capital	80	80	80	80	80	80
Preference Share Capital	-	-	-	-	-	-
Reserves & surplus	1,307	1,590	1,748	2,142	2,716	3,435
Shareholders' funds	1,387	1,670	1,828	2,222	2,796	3,515
Secured loans	161	533	1,046	1,222	1,329	1,179
Unsecured loans (including lease)	96	145	309	207	107	107
Borrowings (including lease)	257	678	1,355	1,429	1,436	1,286
Minority interest	23	27	26	26	26	26
Sources of funds	1,667	2,375	3,210	3,678	4,258	4,828
Gross block	1,329	2,220	3,034	3,384	4,269	5,069
Depreciation	324	453	600	780	990	1,247
Net block	1,005	1,766	2,434	2,604	3,279	3,822
Capital work in progress	21	477	600	600	600	600
Total fixed assets	1,026	2,243	3,034	3,204	3,879	4,422
Unrealised profit	-	-	-	-	-	-
Investments	332	-	74	74	74	74
Inventories	36	43	49	60	83	102
Sundry debtors	129	253	294	330	461	563
Cash and equivalents	190	134	132	236	82	61
Loans and advances	38	48	72	72	72	72
Other current assets	-	-	-	-	-	-
Total current assets	393	478	547	697	697	797
Sundry creditors and others	174	174	197	238	332	405
Provisions	11	38	46	46	46	46
Total CL & provisions	185	212	243	284	378	451
Net current assets	208	266	304	414	320	346
Net Deferred tax	-35	-9	-14	-14	-14	-14
Misc expenditure	135	-125	-188	-	-	-
Uses of funds	1,667	2,375	3,210	3,678	4,258	4,828
Book value per share (INR)	173	209	228	56	70	88

Cash flow statement

(INR crs)

Year to March	FY22	FY23	FY24	FY25E	FY26E	FY27E
Net profit	344	336	336	420	601	747
Add: Depreciation	73	129	147	180	210	257
Add: Misc expenses written off	-132	294	63	-188	0	0
Add: Deferred tax	39	-26	5	0	0	0
Less: Minority Interest	11	29	26	26	27	27
Gross cash flow	313	704	525	386	784	976
Less: Changes in W. C.	124	113	41	5	60	47
Operating cash flow	189	591	484	381	724	929
Less: Capex	158	1347	937	350	885	800
Free cash flow	31	-755	-453	31	-161	129

Capacity expansion to drive growth

Ratios

Year to March	FY22	FY23	FY24	FY25E	FY26E	FY27E
ROAE (%)	30	21	18	19	23	23
ROACE (%)	32	23	18	18	22	23
Debtors (days)	28	42	43	40	40	40
Current ratio	2.1	2.3	2.3	2.5	1.8	1.8
Debt/Equity	0.2	0.4	0.7	0.6	0.5	0.4
Inventory (days)	8	7	7	7	7	7
Payable (days)	39	29	29	29	29	29
Cash conversion cycle (days)	-2	20	21	18	18	18
Debt/EBITDA	0.5	1.1	2.1	1.8	1.3	1.0
Adjusted debt/Equity	0.0	0.3	0.7	0.5	0.5	0.3

Valuation parameters

Year to March	FY22	FY23	FY24	FY25E	FY26E	FY27E
Diluted EPS (INR)	8	8	8	10	14	18
Y-o-Y growth (%)	65	1	-8	27	46	25
CEPS (INR)	51	56	57	14	20	24
Diluted P/E (x)	67	67	72	57	39	31
Price/BV(x)	3	3	2	10	8	6
EV/Sales (x)	3	2	2	8	6	5
EV/EBITDA (x)	9	8	9	29	22	18
Diluted shares O/S	8	8	8	40	40	40
Basic EPS	42	42	39	10	14	18
Basic PE (x)	13	13	14	57	39	31

Capacity expansion to drive growth

Nuvama Wealth and Investment Limited, Eight Floor 801 to 804, Inspire BKC G Block, BKC Main Road, Bandra Kurla Complex, Bandra East, Mumbai-400051

Sandeep Raina

Head of Research – Professional Client Group

Sandeep.raina@nuvama.com

Nuvama Wealth and Investment Limited (Formerly known as Edelweiss Broking Limited) ("NWIL") or ("Research Entity") a company duly incorporated under the Companies Act, 1956 (CIN No U65100GJ2008PLC077462) having its Registered Office situated at Eight Floor 801 to 804, Inspire BKC G Block, BKC Main Road, Bandra Kurla Complex, Bandra East, Mumbai-400051. It is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of NWIL and its Associates (list available on www.nuvamawealth.com) are organized around five broad business groups: Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance

Broking services offered by Nuvama Wealth and Investment Limited under SEBI Registration No. INZ 000005231. Name of the Compliance Officer: Mr Srijith Menon, Email address: complianceofficer.nwil@nuvama.com. Corporate Office Eight Floor 801 to 804, Inspire BKC G Block, BKC Main Road, Bandra Kurla Complex, Bandra East, Mumbai-400051

This Report has been prepared by Nuvama Wealth and Investment Limited (Formerly Edelweiss Broking Limited) [NWIL] in the capacity of a Research Analyst having SEBI Registration No. INH000011103 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NWIL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. NWIL reserves the right to make modifications and alterations to this statement as may be required from time to time. NWIL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NWIL is committed to providing independent and transparent recommendation to its clients. Neither NWIL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of NWIL. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of NWIL and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.

NWIL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the NWIL to present the data. In no event shall NWIL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the NWIL through this report. We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

NWIL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. (c) NWIL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. (d) The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with NWIL. (e) Registration granted by SEBI and certification from NISM in no way guarantee performance of NWIL or provide any assurance of returns to investors and clients.

NWIL or its associates may have received compensation from the subject company in the past 12 months. NWIL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. NWIL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWIL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWIL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or NWIL's associates may have financial interest in the subject company. NWIL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

NWIL has financial interest in the subject companies: No

NWIL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

NWIL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by NWIL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

DISCLAIMERS FOR INTERNATIONAL JURISDICTION

Disclaimer for U.S. Persons

The content of the website does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules. THIS DOCUMENT IS INTENDED SOLELY TO PROVIDE INFORMATION TO THE QUALIFIED INSTITUTIONAL INVESTORS ONLY AND IS NOT MEANT FOR RETAIL INVESTORS. If you are not the intended recipient you must not copy, distribute, or take any action or place reliance on it. If you have received this communication by error, please notify the sender immediately. This communication is intended solely for the person to whom it is addressed and may contain confidential or privileged information. The document is intended to be educational only and not for a marketing or prospecting purpose. The views and opinions expressed as part of this presentation do not necessarily state or reflect those of Nuvama, its holding company(ies), subsidiaries and associates including entities in overseas jurisdictions.

The content of the website or any information contained therein must not be distributed, published, reproduced, or disclosed (in whole or in part) by recipients to any other person. The content of the website must not be acted on or relied on by persons who are not qualified institutional investor. Any investment or investment activity to which this website relates, is available only to qualified institutional investor and will be engaged only with qualified institutional investor. Any person who is not a qualified institutional investor should not act or rely on this website or any of its contents

Disclaimer for U.K. Persons:

The content of the website has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). In the United Kingdom, this document is intended for (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). THIS document IS INTENDED SOLELY TO PROVIDE INFORMATION TO THE QUALIFIED INSTITUTIONAL INVESTORS ONLY AND IS NOT MEANT FOR RETAIL INVESTORS. If you are not the intended recipient you must not copy, distribute, or take any action or place reliance on it. If you have received this communication by error, please notify the sender immediately. This communication is intended solely for the person to whom it is addressed and may contain confidential or privileged information. The content of the document is intended to be educational only and not for a marketing or prospecting purpose. The views and opinions expressed as part of this document do not necessarily state or reflect those of Nuvama, its holding company (ies), subsidiaries and associates including entities in overseas jurisdictions.

Disclaimer for Canadian Persons

The content of the website is NOT MEANT FOR RETAIL INVESTORS. IT IS INTENDED SOLELY TO PROVIDE INFORMATION TO THE PERMITTED CLIENTS ONLY (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). Any products or services described in this document are made available only in accordance with applicable Canadian securities law and only where they may be lawfully offered for sale. If the person accessing this document is not an Ontario Permitted Client, as specified above, then the recipient should not access the same. Nuvama and its group companies is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) Nuvama and its group companies is not registered in the Province of Ontario to trade in securities nor is it registered in the Province of Ontario to provide advice with respect to securities; (ii) Nuvama's head office or principal place of business is located in India; (iii) all or substantially all of Nuvama's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against Nuvama because of the above; and (v) the name and address of Nuvama Group's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario M5J 2T3 Canada. The content of the website must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. This communication must not be acted on or relied on by persons who are not PERMITTED CLIENTS. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a PERMITTED CLIENTS should not act or rely on this communication or any of its contents.

Disclaimer for UAE Persons

The content of the website is INTENDED SOLELY TO PROVIDE INFORMATION TO THE INSTITUTIONAL QUALIFIED INVESTORS ONLY AND IS NOT MEANT FOR RETAIL INVESTORS. Further, the information in this document does not constitute a public offer of securities in the United Arab Emirates and is not intended to be a public offer. The website has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority of the United Arab Emirates or the Dubai Financial Services Authority. The content of the website must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. The website must not be acted on or relied on by persons who are not INSTITUTIONAL QUALIFIED INVESTORS. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a INSTITUTIONAL QUALIFIED INVESTORS should not act or rely on this communication or any of its contents. The content of the website must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. The website must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.

Disclaimer for Australia Persons

Any information set out on the website is only intended for persons who are “Professional Investors” as described in Section 761(G) of the Corporations Act 2001 (as amended). It is not intended to for any other class of persons and may not be relied upon by such persons and is therefore not intended for private individuals or those who would be classified as Retail Clients. All information on the website is general information only and is not to be considered any form of advice (whether investment or otherwise) or a recommendation, solicitation, or an offer to purchase or sell investments or related financial products or any financial services. The receiver of the website should make their own decisions based upon their own financial objectives and financial resources and, if in any doubt, should seek advice from an appropriate independent advisor. Nuvama and its group companies does not hold an Australian Financial Services License and is not licensed in Australia to provide financial product advice or services and is relying on “limited connection relief exemption” when dealing with “Professional Investors” (Wholesale client category) in Australia.

Disclaimer for Singapore Persons

The content of the website IS INTENDED SOLELY TO PROVIDE INFORMATION ONLY TO THE INSTITUTIONAL OR ACCREDITED INVESTORS ONLY AND IS NOT MEANT FOR RETAIL INVESTORS AS DEFINED UNDER THE SECURITIES AND FUTURES ACT “SFA”. If you are not the intended recipient you must not copy, distribute, or take any action or place reliance on it. If you have received this communication by error, please notify the sender immediately. Any such information contained or discussed in the document is subject to change and Nuvama and its group companies shall not have any responsibility to maintain the information made available or to supply any correction therewith. In no event will Nuvama and its group companies be liable for any special direct or indirect or consequential damages which may be incurred from the use of the information made available, even if it has been advised of the possibility of such damages. The company and its employees mentioned in these communications cannot be held liable for any error’s inaccuracies and/or omission howsoever caused. Any opinion or advice if any herein is made on a general basis and is subject to change without notice. The information provided in this document may contain optimistic statements regarding future events or future financial performance of countries, markets, or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided if any in this document. This document has not been reviewed by the Monetary Authority of Singapore “MAS”.

Additional Marketing Disclaimer for all other International Jurisdiction:

The content of this website is restricted in certain jurisdictions and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, by anyone in any jurisdiction in which such an offer or solicitation is not authorised or may not lawfully be made (without compliance with any registration or other legal requirements) or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such offer in any jurisdiction. The above information is for general guidance only, it is the responsibility of receivers to inform themselves as to any income or other tax consequences arising in the jurisdictions in which they are resident or domiciled or have any other presence for tax purposes, as well as any foreign exchange or other fiscal, or legal or regulatory restrictions which are relevant to their particular circumstances in connection with the acquisition, holding or disposal of any securities if any mentioned in this document. This document is strictly private and confidential and may not be reproduced or use for any other purpose and not be provided to any person other than the recipient thereof. If you are not the intended recipient you must not copy, distribute, or take any action or place reliance on it. If you have received this communication by error, please notify the sender immediately. Any such information contained or discussed on the website is subject to change and Nuvama Group or any of its Directors, Employees, agents or representatives shall not have any responsibility to maintain the information made available or to supply any correction therewith. In no event will Nuvama Group or any of its Directors, Employees, agents or representatives, be liable for any special direct or indirect or consequential damages which may be incurred from the use of the information made available, even if it has been advised of the possibility of such damages. The company and its employees mentioned in these communications cannot be held liable for any error’s inaccuracies and/or omission howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in this website may contain optimistic statements regarding future events or future financial performance of countries, markets, or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided therein.

INVESTMENT IN SECURITIES MARKET ARE SUBJECT TO MARKET RISKS. READ ALL THE RELATED DOCUMENTS CAREFULLY BEFORE INVESTING.